FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040091954> ?p ?o ?g. }

• W2040091954 endingPage "41" @default.
• W2040091954 startingPage "34" @default.
• W2040091954 abstract "Nanocrystal-based drug delivery systems provide important tools for ocular formulation development, especially when considering poorly soluble drugs. The objective of the study was to formulate ophthalmic, intraocular pressure (IOP) reducing, nanocrystal suspensions from a poorly soluble drug, brinzolamide (BRA), using a rapid wet milling technique, and to investigate their IOP reducing effect in vivo. Different stabilizers for the nanocrystals were screened (hydroxypropyl methylcellulose (HPMC), poloxamer F127 and F68, polysorbate 80) and HPMC was found to be the only successful stabilizer. In order to investigate both the effect of an added absorption enhancer (polysorbate 80) and the impact of the free drug in the nanocrystal suspension, formulations in phosphate buffered saline (PBS) at pH 7.4 and pH 4.5 were prepared. Particle size, polydispersity (PI), solid state (DSC), morphology (SEM) as well as dissolution behavior and the uniformity of the formulations were characterized. There was rapid dissolution of BRA (in PBS pH 7.4) from all the nanocrystal formulations; after 1 min 100% of the drug was fully dissolved. The effect was significantly pronounced at pH 4.5, where the dissolved fraction of drug was the highest. The cytotoxicity of nanocrystal formulations to human corneal epithelial cell (HCE-T) viability was tested. The effects of the nanocrystal formulations and the commercial product on the cell viability were comparable. The intraocular pressure (IOP) lowering effect was investigated in vivo using a modern rat ocular hypertensive model and elevated IOP reduction was seen in vivo with all the formulations. Notably, the reduction achieved in experimentally elevated IOP was comparable to that obtained with a marketed product. In conclusion, various BRA nanocrystal formulations, which all showed advantageous dissolution and absorption behavior, were successfully formulated." @default.
• W2040091954 created "2016-06-24" @default.
• W2040091954 creator A5004570125 @default.
• W2040091954 creator A5004833492 @default.
• W2040091954 creator A5007696670 @default.
• W2040091954 creator A5008612982 @default.
• W2040091954 creator A5018814025 @default.
• W2040091954 creator A5019302945 @default.
• W2040091954 creator A5024426748 @default.
• W2040091954 creator A5046992296 @default.
• W2040091954 creator A5058595360 @default.
• W2040091954 creator A5060749544 @default.
• W2040091954 creator A5083885412 @default.
• W2040091954 creator A5088017323 @default.
• W2040091954 date "2014-06-01" @default.
• W2040091954 modified "2023-09-29" @default.
• W2040091954 title "Brinzolamide nanocrystal formulations for ophthalmic delivery: Reduction of elevated intraocular pressure in vivo" @default.
• W2040091954 cites W1264540065 @default.
• W2040091954 cites W1580701369 @default.
• W2040091954 cites W1594437063 @default.
• W2040091954 cites W1969373623 @default.
• W2040091954 cites W1969644888 @default.
• W2040091954 cites W1974354891 @default.
• W2040091954 cites W1977555380 @default.
• W2040091954 cites W1979425595 @default.
• W2040091954 cites W1982597434 @default.
• W2040091954 cites W1992242429 @default.
• W2040091954 cites W2006960791 @default.
• W2040091954 cites W2014083454 @default.
• W2040091954 cites W2023344799 @default.
• W2040091954 cites W2028536670 @default.
• W2040091954 cites W2033926534 @default.
• W2040091954 cites W2036262785 @default.
• W2040091954 cites W2054428155 @default.
• W2040091954 cites W2060320802 @default.
• W2040091954 cites W2063339011 @default.
• W2040091954 cites W2064972870 @default.
• W2040091954 cites W2064994319 @default.
• W2040091954 cites W2070051329 @default.
• W2040091954 cites W2071011462 @default.
• W2040091954 cites W2073589440 @default.
• W2040091954 cites W2094002712 @default.
• W2040091954 cites W2106839778 @default.
• W2040091954 cites W2115305419 @default.
• W2040091954 cites W2116855925 @default.
• W2040091954 cites W2118634071 @default.
• W2040091954 cites W2120711134 @default.
• W2040091954 cites W2126691225 @default.
• W2040091954 cites W2139581224 @default.
• W2040091954 cites W2140067957 @default.
• W2040091954 cites W2143644070 @default.
• W2040091954 cites W2159465632 @default.
• W2040091954 cites W3123472196 @default.
• W2040091954 cites W4240661191 @default.
• W2040091954 cites W4376595529 @default.
• W2040091954 doi "https://doi.org/10.1016/j.ijpharm.2014.03.048" @default.
• W2040091954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24680962" @default.
• W2040091954 hasPublicationYear "2014" @default.
• W2040091954 type Work @default.
• W2040091954 sameAs 2040091954 @default.
• W2040091954 citedByCount "94" @default.
• W2040091954 countsByYear W20400919542014 @default.
• W2040091954 countsByYear W20400919542015 @default.
• W2040091954 countsByYear W20400919542016 @default.
• W2040091954 countsByYear W20400919542017 @default.
• W2040091954 countsByYear W20400919542018 @default.
• W2040091954 countsByYear W20400919542019 @default.
• W2040091954 countsByYear W20400919542020 @default.
• W2040091954 countsByYear W20400919542021 @default.
• W2040091954 countsByYear W20400919542022 @default.
• W2040091954 countsByYear W20400919542023 @default.
• W2040091954 crossrefType "journal-article" @default.
• W2040091954 hasAuthorship W2040091954A5004570125 @default.
• W2040091954 hasAuthorship W2040091954A5004833492 @default.
• W2040091954 hasAuthorship W2040091954A5007696670 @default.
• W2040091954 hasAuthorship W2040091954A5008612982 @default.
• W2040091954 hasAuthorship W2040091954A5018814025 @default.
• W2040091954 hasAuthorship W2040091954A5019302945 @default.
• W2040091954 hasAuthorship W2040091954A5024426748 @default.
• W2040091954 hasAuthorship W2040091954A5046992296 @default.
• W2040091954 hasAuthorship W2040091954A5058595360 @default.
• W2040091954 hasAuthorship W2040091954A5060749544 @default.
• W2040091954 hasAuthorship W2040091954A5083885412 @default.
• W2040091954 hasAuthorship W2040091954A5088017323 @default.
• W2040091954 hasConcept C101335993 @default.
• W2040091954 hasConcept C11432220 @default.
• W2040091954 hasConcept C118487528 @default.
• W2040091954 hasConcept C147789679 @default.
• W2040091954 hasConcept C150903083 @default.
• W2040091954 hasConcept C15920480 @default.
• W2040091954 hasConcept C171250308 @default.
• W2040091954 hasConcept C175854130 @default.
• W2040091954 hasConcept C178790620 @default.
• W2040091954 hasConcept C185592680 @default.
• W2040091954 hasConcept C187530423 @default.
• W2040091954 hasConcept C192562407 @default.
• W2040091954 hasConcept C207001950 @default.
• W2040091954 hasConcept C2777897440 @default.

• next